Primary study on application of cell-free fetal DNA (cffDNA) in non-invasive prenatal testing of β-thalassemia
Main Article Content
Abstract
β-thalassemia is a common autosomal recessive disorders, caused by mutations in the β-globin gene. It severely influences the physical and mental development of affected children and place an immense burden of care and treatment on the family and society. Therefore, the prenatal screening of β-thalassemia to control its increase in the community is anessential part of preventive genetics. Currently, besides traditional prenatal diagnostic tests that requires invasive sampling techniques such as amniocentesis or chorionic villous sampling (CVS), the use of cffDNA for non-invasive prenatal testing of β-thalassemia is a new, safer, and more effective direction. In this study, we extracted and enriched the percent of cffDNA in the maternal peripheral blood as well as optimized AS-PCR to detect three most common β-thalassemia mutations CD17, CD26, and CD41/42. Presence or absence of the paternal mutant allele was then correctly determined in all of 7 cases compared to fetal genotyping that determined with amniocentesis.
References
2. Stumm M, Wegner R-D, Hofmann W., Cell-free fetal DNA in maternal blood: new possibilities in prenatal diagnostics, Laboratoriumsmedizin, (2012), 36(5).
3. Sekizawa K., YokokawaY., SugitoY., IwasakiM., YukimotoY., Ichizuka K., Saito H.,, Okai T., Evaluation of bidirectional transfer of plasma DNA through placenta, Hum Genet, (2003), 113(4): 307-310.
4. Chan K.C., Zhang J., Hui A.B., Wong N., Lau T.K., Leung T.N., Lo K.W., Huang D.W., Lo Y.M., Size distributions of maternal and fetal DNA in maternal plasma, Clin Chem, (2004), 50(1):88-92.
5. Lun F.M., Tsui N.B., Chan K.C., Leung T.Y., Lau T.K., Charoenkwan P., Chow K.C., Lo W.Y., Wanapirak C., Sanguansermsri T., Cantor C.R., Chiu R.W., Lo Y.M. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci, (2008); 105(50):19920–19925.
6. Li Y., Di Naro E., Vitucci A., Zimmermann B., Holzgreve W., Hahn S., Detection of paternally inherited fetal point mutations for β-thalassemia using size-fractionated cell-freeDNA in maternal plasma, JAMA, (2005), 293(7):843-849.
7. Chen J.J., Tan J.A., Chua K.H., Tan P.C., George E., Non-invasive prenatal diagnosis using fetal DNA in maternal plasma: a preliminary study for identification of paternally-inherited alleles using single nucleotide polymorphisms, BMJ Open, (2015), 5(7):e007648.
8. Ramezanzadeh M., Salehi M., Farajzadegan Z., Kamali S., Salehi R., Detection of paternally inherited fetal point mutations for β-thalassemia in maternal plasma using simple fetal DNA enrichment protocol with or without whole genome amplification: an accuracy assessment, J Matern Fetal Neonatal Med, (2016), 29(16): 2645-2649.
9. Galbiati S., Monguzzi A., Damin F., Soriani N., Passiu M., Castellani C., Natacci F., Curcio C., Seia M., Lalatta F., Chiari M., Ferrari M., Cremonesi L., COLD-PCR and microarray: two independent highly sensitive approaches allowing the identification of fetal paternally inherited mutations in maternal plasma, J Med Genet, (2016), 53(7):481-487.
10. Xiong L., Barrett A.N., Hua R., Tan T.Z., Ho S.S., Chan J.K., Zhong M., Choolani M. Non-invasive prenatal diagnostic testing for beta-thalassaemia using cell-free fetal DNA and next generation sequencing, Prenat Diagn, số (2015), 35(3):258-265.
11. Little S., Amplification-Refractory Mutation System (ARMS) analysis of point mutations. Curr Protoc Hum Genet, (2001), Chapter 9:Unit 9.8.